To include your compound in the COVID-19 Resource Center, submit it here.

Juno's JCAR015 Phase II on clinical hold

Juno Therapeutics Inc. (NASDAQ:JUNO) fell $11.68 (29%) to $29.14 in early after-hours trading Thursday after FDA placed a clinical hold on the Phase II ROCKET trial of JCAR015 to treat relapsed or

Read the full 324 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE